Biotech · Public company · West Conshohocken, PA, US
Madrigal Pharmaceuticals, Inc.
Ticker MDGL · SEC CIK 0001157601
Track this companyFree. Adds Madrigal Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials178 recruiting or active
Pipeline programs20From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline20
- Liver BiopsyPhase 3 · NASH - Nonalcoholic SteatohepatitisClinicalTrials.gov · fetched Nov 12, 2026
- MGL-3196Phase 3 · NASH - Nonalcoholic SteatohepatitisClinicalTrials.gov · fetched Nov 12, 2026
- ResmetiromPhase 3 · Non-Alcoholic Fatty Liver DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- ResmetiromPhase 3 · NASHClinicalTrials.gov · fetched Nov 12, 2026
- MGL-3196Phase 2 · Non-alcoholic SteatohepatitisClinicalTrials.gov · fetched Nov 12, 2026
- ResmetiromPhase 2 · MASH - Metabolic Dysfunction-Associated SteatohepatitisClinicalTrials.gov · fetched Nov 12, 2026
- ResmetiromPhase 2 · MASHClinicalTrials.gov · fetched Nov 12, 2026
- 100 mg Resmetirom TabletPhase 1 · Renal ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
- ClopidogrelPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- MGL-3196Phase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- MGL-3196Phase 1 · Hepatic ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
- MGL-3196 CapsulePhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- MGL-3196 TabletPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- Pioglitazone 15mgPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- RosuvastatinPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- SimvastatinPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- VIA-3196Phase 1 · Drug SafetyClinicalTrials.gov · fetched Nov 12, 2026
- ACTOS/pioglitazoneMASH - Metabolic Dysfunction-Associated SteatohepatitisClinicalTrials.gov · fetched Nov 12, 2026
- FARXIGA/dapagliflozinMASH - Metabolic Dysfunction-Associated SteatohepatitisClinicalTrials.gov · fetched Nov 12, 2026
- RezdiffraMASH - Metabolic Dysfunction-Associated SteatohepatitisClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials17
- Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 FibrosisPHASE4 · RECRUITING · started Oct 7, 2026ClinicalTrials.gov NCT07848191 · fetched Nov 12, 2026
- Resmetirom in Patients With MASH and HFpEFPHASE1 · RECRUITING · started Sep 1, 2026ClinicalTrials.gov NCT07830758 · fetched Nov 12, 2026
- Study of Resmetirom in Children and Adolescents With MASHPHASE2 · RECRUITING · started Aug 1, 2026ClinicalTrials.gov NCT07763015 · fetched Nov 12, 2026
- Rezdiffra Pregnancy and Lactation RegistryRECRUITING · started Mar 4, 2026ClinicalTrials.gov NCT07541469 · fetched Nov 12, 2026
- Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASHPHASE2 · RECRUITING · started Dec 29, 2025ClinicalTrials.gov NCT07335601 · fetched Nov 12, 2026
- A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal FunctionPHASE1 · COMPLETED · started Mar 6, 2024ClinicalTrials.gov NCT06397872 · fetched Nov 12, 2026
- A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)PHASE3 · ACTIVE_NOT_RECRUITING · started Aug 26, 2022ClinicalTrials.gov NCT05500222 · fetched Nov 12, 2026
- A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)PHASE3 · ACTIVE_NOT_RECRUITING · started Jul 9, 2021ClinicalTrials.gov NCT04951219 · fetched Nov 12, 2026
- A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease PatientsPHASE3 · COMPLETED · started Dec 16, 2019ClinicalTrials.gov NCT04197479 · fetched Nov 12, 2026
- Drug Interaction Study of MGL-3196 With ClopidogrelPHASE1 · COMPLETED · started Jul 26, 2019ClinicalTrials.gov NCT04671069 · fetched Nov 12, 2026
- A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and FibrosisPHASE3 · ACTIVE_NOT_RECRUITING · started Mar 28, 2019ClinicalTrials.gov NCT03900429 · fetched Nov 12, 2026
- Drug Interaction Study of MGL-3196 With PioglitazonePHASE1 · COMPLETED · started Nov 9, 2018ClinicalTrials.gov NCT04671056 · fetched Nov 12, 2026
- Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control SubjectsPHASE1 · COMPLETED · started Oct 25, 2018ClinicalTrials.gov NCT04643795 · fetched Nov 12, 2026
- Bioavailability Study of MGL-3196 Tablets Compared to CapsulesPHASE1 · COMPLETED · started Feb 5, 2018ClinicalTrials.gov NCT03413124 · fetched Nov 12, 2026
- Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)PHASE2 · COMPLETED · started Oct 18, 2016ClinicalTrials.gov NCT02912260 · fetched Nov 12, 2026
- Drug Interaction Study of MGL-3196 With Rosuvastatin and SimvastatinPHASE1 · COMPLETED · started Sep 1, 2015ClinicalTrials.gov NCT02542969 · fetched Nov 12, 2026
- Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy SubjectsPHASE1 · COMPLETED · started Jun 1, 2011ClinicalTrials.gov NCT01367873 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 3, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 3, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 12, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Jul 30, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 30, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 17, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 28, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Feb 19, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Feb 19, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jan 30, 2026 · fetched Nov 12, 2026